Female infertility in anovulation

Active Ingredient: Urofollitropin

Indication for Urofollitropin

Population group: women, only adults (18 - 65 years old)

Urofollitropin is indicated for the treatment of female infertility in anovulation (including polycystic ovarian disease (PCOD)) in women who have been unresponsive to treatment with clomiphene citrate.

For this indication, competent medicine agencies globally authorize below treatments:

75-225 IU once daily

Route of admnistration


Defined daily dose

75 - 225 [iU]

Dosage regimen

From 75 To 225 [iU] once every day

Detailed description

The object of urofollitropin therapy is to develop a single Graafian follicle from which the oocyte will be liberated after the administration of human chorionic gonadotropin (hCG).

Urofollitropin therapy should start within the initial 7 days of the menstrual cycle. The recommended initial dose of urofollitropin is 75 IU daily, which should be maintained for at least 7 days. Based on clinical monitoring (including ovarian ultrasound alone or in combination with measurement of oestradiol levels) subsequent dosing should be adjusted according to individual patient response. Adjustments in dose should not be made more frequently than every 7 days. The recommended dose increment is 37.5 IU per adjustment and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned.

When an optimal response is obtained a single injection of 5,000 to 10,000 IU hCG should be given 1 day following the last urofollitropin injection. The patient is recommended to have coitus on the day of and the day following hCG administration. Alternatively intrauterine insemination may be performed. Patients should be followed closely for at least 2 weeks after hCG administration. If an excessive response to urofollitropin is obtained treatment should be stopped and hCG withheld, and the patient should use a barrier method of contraception or refrain from having coitus until the next menstrual bleeding has started.

Active ingredient


Urofollitropin contains a highly purified preparation of urinary FSH extracted from the urine of postmenopausal women. FSH stimulates ovarian follicular growth and development as well as gonadal steroid production in women who do not have primary ovarian failure.

Read more about Urofollitropin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.